Funds and ETFs Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 14:32:39 14/06/2024 BST 5-day change 1st Jan Change
1,033 USD +0.59% Intraday chart for Regeneron Pharmaceuticals, Inc. +2.57% +16.88%
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,027 USD
Average target price
1,047 USD
Spread / Average Target
+2.02%
Consensus
  1. Stock Market
  2. Equities
  3. REGN Stock
  4. Funds and ETFs Regeneron Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW